|drug2504||Nasal Swab Wiki||1.00|
|drug1051||Convalescent Plasma 2 Units Wiki||1.00|
|drug1050||Convalescent Plasma 1 Unit Wiki||1.00|
|D012327||RNA Virus Infections NIH||0.41|
|D014777||Virus Diseases NIH||0.11|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
Performance of the LumiraDx SARS-CoV-2 Ag assay will be assessed by comparison to a reference method.
Description: Evaluation of performance of the device versus a reference method using standard qualitative comparison techniques (Percent Agreement)Measure: Performance Evaluation Time: 4 months
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports